L
Lumen Bioscience
Biotech & Life Sciences · Seattle, United States · Founded 2017
Discovers, develops and manufactures biologic drugs and vaccine candidates for several prevalent, worldwide diseases MoreLess
Lumen Bio is a biotechnology startup that is revolutionizing the development and distribution of biologic drugs. Biologic drugs are products that are produced from living organisms or contain components of living organisms. These drugs have immense potential in treating various diseases but have been limited by the lack of scalable technology. Lumen Bio is addressing this gap by leveraging its patented technology to develop these drugs faster, at a lower cost, and with less risk than traditional methods.
The company operates in the biopharmaceutical market, serving a broad range of clients including hospitals, healthcare providers, and patients suffering from diseases such as Inflammatory Bowel Disease (IBD) and metabolic diseases. These are conditions that have been largely neglected by the healthcare industry due to the high costs associated with their treatment.
Lumen Bio's business model is centered around the development and commercialization of biologic drugs. The company makes money by selling these drugs to healthcare providers and hospitals. By reducing the cost and time of development, Lumen Bio is able to offer these drugs at a more affordable price, thereby increasing access for patients who need them.
In addition, Lumen Bio is also addressing other health issues such as gastrointestinal symptoms, which affect a significant number of patients, and diseases that are a leading cause of death worldwide. The company is also developing therapies for mild-to-moderate Crohn's disease and is working to protect travelers and US servicemembers from health risks.
Keywords: Biotechnology, Biologic Drugs, Patented Technology, Healthcare Providers, Hospitals, Inflammatory Bowel Disease, Metabolic Diseases, Drug Development, Affordable Treatment, Scalable Technology.
Company overview
Lumen Bioscience company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2017
- Headquarters
- Seattle, United States
- Employees
- 112
- Open positions
- None listed
- Dealroom signal
- 87.2
Valuation & funding
Lumen Bioscience funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Oct 2025 | $30M | $252M | Matt Horner · WestRiver Group · Jerry Yang · Jeff Raikes | ↗ |
| LATE VCOther financing | Sep 2023 | $17M | $252M | Undisclosed | ↗ |
| DEBTDebt | Sep 2023 | $17M | — | Undisclosed | ↗ |
| GRANTOther financing | May 2023 | $8.8M | — | US Department of War | ↗ |
| GRANTOther financing | Dec 2022 | $3.6M | — | MTEC | ↗ |
| LATE VCOther financing | Jul 2022 | Undisclosed | ↗ | ||
| GRANTOther financing | Feb 2021 | CARB-X | — | ||
| SERIES BOther financing | Sep 2020 | Columbia Pacific Advisors · WestRiver Group · Jim Roberts · Brian Finrow | — | ||
| SERIES AOther financing | Dec 2017 | Bioeconomy Capital | — | ||
| GRANTOther financing | Aug 2017 | Undisclosed | — |
Growth signals
Lumen Bioscience website traffic
Latest recorded traffic for Lumen Bioscience is 5.4K monthly website visits, up 20% over the last three months. Lumen Bioscience's team grew 8.7% over the past year.
Hiring
Open positions at Lumen Bioscience
Current openings linked to this company in Dealroom.
Comparisons
Lumen Bioscience compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Lumen Bioscience's talent
Source: Dealroom Talent Intelligence.
Investors
16 investors on Lumen Bioscience's cap table
Sourced from Dealroom's funding and investor records.
















Global footprint
Where Lumen Bioscience has talent and traffic
team presence
In the news
Latest news about Lumen Bioscience
Recent press, funding announcements, and product moves mentioning Lumen Bioscience — open to read from the original sources.
Market sentiment
What the market is saying about Lumen Bioscience
An AI-synthesized read of the highest-engagement posts about Lumen Bioscience on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lumen Bioscience’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







